Runt-related transcription factor (RUNX) family (RUNX)

The Runt-related transcription factor (RUNX) family consists of three members—RUNX1, RUNX2, and RUNX3—that act as master regulators of gene expression during development and cellular differentiation. These proteins are characterized by a highly conserved 128-amino acid Runt domain, which is essential for DNA binding and heterodimerization with the co-factor Core-binding factor subunit beta (CBFβ) to enhance transcriptional activity (UniProt, 2024). RUNX1 is critical for the establishment of definitive hematopoiesis, while RUNX2 is the primary driver of osteoblast differentiation and bone formation, and RUNX3 plays significant roles in neurogenesis and immune cell development (PubMed, PMID: 28254961). Dysregulation of RUNX factors is a hallmark of various pathologies; for instance, RUNX1 mutations and translocations are frequently observed in acute myeloid leukemia, and RUNX2 overexpression is linked to bone metastasis in solid tumors (NIH, 2023). Therapeutic strategies targeting the RUNX family often focus on disrupting the RUNX/CBFβ interaction or inhibiting the DNA-binding capacity of oncogenic fusion proteins (PubChem, 2024). However, because these factors are essential for normal physiological processes like blood cell production and bone maintenance, achieving selectivity and minimizing systemic toxicity remain significant challenges in drug development.

Other names

Core-binding factor alphaCBFAPolyomavirus enhancer-binding protein 2PEBP2AML transcription factorsRunt domain transcription factors

Inhibition of the protein-protein interaction between the RUNX Runt domain and the CBFβ subunit, or direct competitive inhibition of DNA binding at the Runt domain to modulate downstream gene expression.